SYK-selective kinase inhibitor
oral, completed Ph. I in HV
from optimization of prior candidate
ACS Med. Chem. Lett. Feb. 12, 2020
Gilead Sciences, Seattle, WA
GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)